1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market.The stock is down by 74% over the trailing-12-month period and, at under $4 per share, is barely above its 52-week low. Still, Wall Street analysts are bullish on Iovance. Their lowest price target is $6, the highest is $32, and the average is $19.54, according to Yahoo! Finance.Do Iovance's prospects justify these projections? Here's what investors need to know about this small-cap biotech company.Continue reading
Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market.
The stock is down by 74% over the trailing-12-month period and, at under $4 per share, is barely above its 52-week low. Still, Wall Street analysts are bullish on Iovance. Their lowest price target is $6, the highest is $32, and the average is $19.54, according to Yahoo! Finance.
Do Iovance's prospects justify these projections? Here's what investors need to know about this small-cap biotech company.
